Meeting
2013 ASCO Annual Meeting
In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).
Authors
Cesar Serrano-Garcia
Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Cesar Serrano-Garcia , Michael C. Heinrich , Meijun Zhu , Chandrajit P. Raut , Grant Eilers , Gloria Ravegnini , George D. Demetri , Sebastian Bauer , Jonathan A. Fletcher , Suzanne George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Citation
J Clin Oncol 31, 2013 (suppl; abstr 10510)
DOI
10.1200/jco.2013.31.15_suppl.10510
Abstract #
10510
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST).
First Author: Michael C. Heinrich
Poster
2011 ASCO Annual Meeting
The effect of crenolanib (CP-868,596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors.
First Author: M. C. Heinrich
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Exploration of drug resistance in advanced gastrointestinal stromal tumor.
First Author: Hao Xu